Egg Banking Makes National News on Good Morning America and Time Magazine
New York, New York (PRWEB) July 23, 2015 -- Progyny, the first company to provide fertility patients with easy accessibility to high quality doctors, price transparency and financing would like to provide new, important analysis on the Good Morning America piece on egg banking. Although GMA included valid points on the pros and cons of egg banking, the segment failed to mention how age is a critical determining factor when deciding to freeze your eggs. In addition to age being a critical factor, there is new science in egg freezing called vitrification, which is a flash freezing of the eggs shown to have improved thaw rates significantly.
The Time magazine article, as well as the GMA segment, highlighted that live-birth rates from egg freezing cycles are about 24%, but didn’t break the average down by age or freezing method. And while egg freezing doesn’t have a 100% guarantee, Progyny and its egg freezing program, EggBanxx, believes these success rates will most likely double in the next few years as younger women choose to freeze eggs and vitrification gains widespread adoption.
“At an EggBanxx event last fall, Dr. Nicole Noyes of NYU Fertility cited a 42% live-birth rate in patients ages 25-34, a 37% live-birth rate in patients ages 35-40, and 33% for patients ages 41-42”, said Gina Bartasi, CEO of Progyny. “We feel confident that success rates will continue to improve and where you freeze your eggs does matter. Selecting from a vetted list of high-quality doctors and having financing helps more women gain access to egg freezing”.
As a woman ages, both the quantity and quality of her eggs diminish and her chance of conceiving a child after age 40 decreases to 5%. Progyny recommends the ideal age for women to freeze their eggs is between 25 and 35 years old. “We realize that it can also be challenging financially to afford egg freezing when you’re in your late 20s to early 30s, so that’s why EggBanxx provides exclusive pricing and financing”, Bartasi added.
The Time magazine article pointed out that egg banking has increased tenfold in the last five years. And, according to a recent poll, 73% of millennials say they are interested in egg freezing, so this important option is gaining in efficacy and public opinion, and with it, continued investments by fertility doctors to improve their technique and success rates.
The science behind freezing eggs is also much better today than it was only a few years ago. In the last couple of years, vitrification (flash freezing of eggs) has improved the thaw process versus the older method of slowly freezing the eggs. The traditional slow freezing process allowed for ice crystals to form on the eggs, and when thawed, the crystals would negatively affect the nucleus of the egg. Vitrification prevents ice crystals from forming on the eggs, therefore allowing for a much higher yield of the frozen eggs when they’re thawed.
We applaud Time Magazine and Good Morning America for highlighting this new technology and bringing this important issue to the forefront. “Egg freezing is not a guarantee and can be expensive, but for those who want a child at some point in life, it’s an option to consider”, Bartasi concluded.
Progyny’s portfolio of products and services includes: EevaTM Test, the first and only non-invasive, FDA-cleared, time-lapse imaging system with a proprietary algorithm to consistently and objectively assess early embryo development milestones; IVFAdvantage, Progyny's no-restriction IVF package plan, offering bundled treatment plans with price transparency, scheduling assistance, financing and preferred appointment times at top clinics across the country; EggBanxx, the country’s leading network of elite fertility doctors specializing in vitrification, which is on a mission to empower young, professional women to take charge of their reproductive health by proactively preserving their fertility; and FertilityAuthority.com, the country’s leading patient-matching technology platform serving the fertility industry through education, patient support, pricing transparency and financing.
About The Company:
Progyny is the first company to provide fertility patients with easy accessibility to high quality doctors, price transparency, and financing, coupled with extraordinary clinical expertise and proprietary clinical solutions. Rooted in clinical excellence and serving as a champion for the consumer, the company is committed to helping ensure that patients control their fertility journey and achieve the best possible outcome. Progyny is privately held and its investors include Kleiner Perkins Caufield & Byers, TPG Biotech, SR One and Merck Serono Ventures. The company is headquartered in New York, NY, with operations in Menlo Park, CA. For more information, please visit http://www.progyny.com.
Contact:
Robin McCarthy
Progyny, SVP of Marketing
[email protected]
646-350-0748
Robin McCarthy, Progyny, http://www.Progyny.com, 646-350-0748, [email protected]
Share this article